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come of interest was cost per decreased puff of rescue
medication per twenty eight days. RESULTS: Leval-
buterol (1.25 mg) decreased puffs by 7.5 over twenty
eight days. However, the average expected costs for treat-
ment with racemic albuterol (2.5 mg) is $116.94/month,
$171.46/month for levalbuterol (0.63 mg) and $182.33/
month for levalbuterol (1.25 mg). Cost-effectiveness ra-
tios were $8.35, $24.50, and $8.80 for albuterol (2.5
mg), levalbuterol (0.63 mg) and levalbuterol (1.25 mg),
respectively. Results were unchanged after sensitivity
analyses. CONCLUSIONS: Levalbuterol (1.25 mg) was
beneficial over racemic albuterol (2.5 mg) in decreasing
puffs of rescue medication over twenty eight days, but at
an additional cost. An incremental cost-effectiveness anal-
ysis demonstrated it costs $9.73 for each additional de-
creased puff per day. The decision-maker needs to evalu-
ate whether the additional effect is worth the added cost.
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OBJECTIVES: Despite their complexity appropriate use of
asthma inhaled medicines is crucial to ensure optimal drug
delivery to the airways. We describe the validation of an
instrument to assess inhalation skills in children. METH-
ODS: The instrument includes a breakdown of the steps
necessary for appropriate inhalation. We videotaped 25
children taking a placebo inhaler (metered dose inhaler
(MDI), MDI with AeroChamber® (MDI-AE®), and Dis-
kus®). A gold standard (GS) was developed by agreement
of two asthma experts watching the videotaped demon-
strations. Twenty-one raters scored the randomly ordered
demonstrations twice within a 2-week interval (sessions 1
and 2). Intra-class correlation coefficients (ICCs) were cal-
culated to assess validity (comparing GS to raters’ scores),
interrater reliability, and test-retest reliability for each step
of the inhalation. RESULTS: ICCs varied considerably by
both, the device and the step. In session 1, a small propor-
tion of raters agreed with the GS on whether patients actu-
ated the MDI and inhaled simultaneously (9.5%, ICCs
0.62 to 0.74) and whether patients hold their breath
(19%, ICCs 0.62 to 1.00). A better agreement was ob-
served for the MDI-AE® where actuation (43%, ICCs
0.43 to 0.56) and inhalation (57%, ICCs 0.43) are two
separate steps. The best interrater agreement was on the
shaking of the MDI (ICC  0.83) and the MDI-AE®
(ICC  0.74). Agreement for the Diskus® was poor for
all steps. Results for session 2 were similar. The best in-
tra-rater agreement was for the Diskus® (ICCs  1 for 5
steps), though only a small proportion of raters agreed on
these steps (5% to 21%). CONCLUSIONS: There was
large variability within and between raters’ scores. Some
steps were better assessed than others. These results sug-
gest that in addition to a detailed instrument, training of
raters is crucial to obtain a valid assessment of the child-
rens’ inhalation technique.
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OBJECTIVES: The study involved validating the scaling
properties of patient-physician interaction scale in a pul-
monary specialty clinic using a clinic-specific scale
through the implementation of Rasch analysis. DATA:
Cross-sectional data from 65 adult asthma patients at the
University of Illinois Asthma clinic was used. Physician
interaction was measured using eight Likert-type items.
Patients responded from “strongly disagree” (1) to
“strongly agree” (4). METHODS: Scaling properties
were assessed by investigating its fit to a Partial Credit
Rasch Rating scale model that enabled item-by-item anal-
ysis. Winsteps® was used for analysis. Model determined
scale robustness in terms of unidimensionality, additivity
and functioning of the rating scale. RESULTS: Analyses
found person separation index of 1.86 with reliability of
0.77. The mean patient measure (0.69 logit) was greater
than mean difficulty of items (0.00 logit) implying patient
ability was greater than item difficulty. On average, or-
dering of items found item ‘physician instructed patients
on home steroid treatment’ (STETX) had the highest
logit measure of 0.69, however it misfitted the model.
Item ‘physician asked about smoking habits’ (ASKSMOK)
had lowest measure of 0.70 logits. Fit statistics revealed
high infit and outfit mean square (MNSQ) values (1.4) for
16 patients. Seven items had MNSQ values within desired
range of 0.6–1.4. CONCLUSIONS: Items exhibited ade-
quate reliability in separating persons, but they displayed
ceiling and floor effects in measurement. Some evidence of
construct validity was established since only one item misfit-
ted the model. Item STETX was the most difficult to en-
dorse (higher on construct), since it might not be applicable
to all, but severe asthmatics. Item ‘ASKSMOK’ was easiest
to endorse, probably because it is a standard asthma care
question. Nevertheless, misfitting persons implied inappro-
priate measurement of some patient attitudes. Thus, some
plausibility in the unidimensionality and validity of the scale
existed, and it exhibited moderate scaling properties.
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